## Problem Statement

User just completed an autonomous /research run (Mission Control L1, run-id `2026-05-23-1400-research-aou-prs-ancestry`) on the topic "All of Us research program polygenic risk score ancestry-stratified accuracy 2025". This was Phase 2b L1 harness-discoverability validation per the user's L0→L3 autonomy roadmap (file: C:\Users\Farshad\.claude\plans\try-again-we-got-mossy-catmull.md, also at C:\Users\Farshad\.claude\plans\L0_to_L3_Autonomy_Path_Plan.md).

User's request: "please analyse results and give me best recommendations for moving forward."

Three vectors of "moving forward" are plausible, and they ARE NOT mutually exclusive. Codex should weigh which deserve priority and surface tradeoffs the user may not have considered:

A. Research-side moving forward — given the new AoU PRS findings + the 5 documented honest gaps, is more research needed? Which gaps are blocking? Or is the research adequate as direction-setting evidence and the user should ACT on it (one of vectors B / C)?

B. DNA decoder product-side moving forward — the AoU findings + the prior PRS cross-ancestry portability research (file: dna_decode/research_outputs/polygenic-risk-score-cross-ancestry-portability-2025-2026.md) feed directly into the DNA decoder marketing verdict v2 (file: C:\Users\Farshad\.claude\plans\DNA_Decoder_Marketing_Panel_Verdict_v2_PM_Ready_2026-05-22.md). What concrete product-positioning decisions or content updates do these findings unlock?

C. Mission Control autonomy-stack-side moving forward — Phase 2b L1 validation is now complete with TWO successful runs (manual 2026-05-22 + harness-invocation 2026-05-23). Per the L0→L3 plan, the next phase is Phase 4 (L2 cross-department routing, 10-14 hr, 2-3 sessions). Should the user advance to Phase 4 next, or first accumulate more L1 usage to surface design flaws before adding L2 complexity?

## Proposed Plan / Idea

The user has not proposed a specific plan. This is an open-ended "what should I do next?" question. Default candidate paths Claude would suggest (Codex should evaluate critically):

Option 1: Drill deeper on the research before acting — recover the 5 honest gaps:
1. AoU Communications Medicine peer-reviewed paper (Nature group, publisher-blocked HTTP 303) via Unpaywall OA-mirror or PMC alternate ID
2. bioRxiv full text (HTTP 403) — primary source for AoU 245K WGS scale claims
3. T2D paper per-ancestry validation R-squared numerics
4. AoU official PRS performance dashboard (not surfaced)
5. AF PRS preprint peer-review status (Research Square — may shift on revision)

Option 2: Update DNA decoder marketing verdict v2 with the new findings:
- Cite the AoU AF PRS European → African gap (1.89 → 1.39 OR/SD; AUROC 0.646 → 0.573) as concrete ancestry-stratification numbers
- Use the prostate cancer 1.61 (Middle Eastern) → 2.19 (American) finding as a counter-narrative to "EUR PRS performs best universally"
- Strengthen the technical-buyer evidence package per the verdict v2 flagged technical-buyer demand
- Cite ~3x non-EUR / ~8x multi-population AoU diversity ratio as anchor for product positioning

Option 3: Advance to Phase 4 (L2 cross-department routing) — build /mission-control multi-department orchestration:
- Step 4.1: Multi-department orchestration with milestone-checkpoint pause (4-6 hr)
- Step 4.2: 2-3 real cross-department validation runs (3-6 hr)
- L2 promotion gate: 2-3 successful cross-department runs

Option 4 (hybrid): do Option 2 (cheap, high product-impact, uses sunk research cost) THEN Option 3 (start Phase 4). Defer Option 1 unless a specific product claim hits a verification wall.

## Constraints and Context

- Current state: L0-actual / L1-actual (just promoted via Phase 2b second successful run).
- Budget reality: user has finite session/token budget. The L0→L3 plan estimates 60-80 hr total across 3-5 months. Steady weekly cadence assumed.
- Empirical-validation discipline: the autonomy-ladder spec warns "N successful runs of a flawed pattern means N undetected failures, not safety." Building L2 on L1 with only 2 runs is light empirical foundation.
- DNA decoder is a real product the user is building (separate session, but spans the same workspace). Research findings have actionable consequences there.
- User preference: "lets go with recommendations" — repeatedly stated execute-mode preference, but expects Claude to challenge before acting.
- No L4/L5 ever per ratified decision (production deploys human-gated forever).
- Research-side notes: survival rate was 13/17 (76% — well above the 80%-rejection escalation threshold). 4 rejected rows were all the SAME failure mode: "(same paper)" quote-shorthand on AUROC pair-rows. This is a process artifact, not a content quality signal. The 5 honest gaps are real research-content limitations though.
- Tech stack for product side (DNA decoder): XGBoost on Nucleotide Transformer (NT) frozen embeddings; cohort sizes 12-150 strains; cipro AMR prediction is the lead use case. Marketing verdict v2 framed it as either (a) consumer-facing genealogy/wellness product (B2C) or (b) clinical-decision-support tool (B2B). The PRS ancestry findings have different weight depending on framing.

Key files to review:
- C:\Users\Farshad\PythonProjects\dna_decode\research_outputs\all-of-us-prs-ancestry-stratified-accuracy-2025-2026-05-23.md (just-written supported memo, 13 rows)
- C:\Users\Farshad\PythonProjects\dna_decode\research_outputs\all-of-us-prs-ancestry-stratified-accuracy-2025-2026-05-23_unsupported.md (4 rejected rows + recovery paths)
- C:\Users\Farshad\PythonProjects\dna_decode\research_outputs\polygenic-risk-score-cross-ancestry-portability-2025-2026.md (prior Phase 2b memo, 17 rows)
- C:\Users\Farshad\PythonProjects\dna_decode\research_outputs\_followup_queue.md (15 active candidates across 3 memos)
- C:\Users\Farshad\PythonProjects\dna_decode\mission-control-runs\2026-05-23-1400-research-aou-prs-ancestry\audit-trail.md (just-finalized COMPLETED)
- C:\Users\Farshad\.claude\plans\try-again-we-got-mossy-catmull.md (the L0→L3 autonomy plan)
- C:\Users\Farshad\.claude\plans\DNA_Decoder_Marketing_Panel_Verdict_v2_PM_Ready_2026-05-22.md (DNA decoder product verdict)

You are free to read any files in the repo you need.

## Review Instructions

- You are a critical reviewer. Challenge the framing — do not validate it.
- Read the suggested files and any others you need before critiquing. List all files you read.
- Critique first, then propose alternatives only where you find meaningful gaps.
- Review through these lenses in priority order:
  1. Correctness / Feasibility — does the recommended path actually use the new research findings, or does it pretend to?
  2. Risks / Regressions — what blind spot in vectors A/B/C did Claude miss?
  3. Complexity / Maintenance cost — is the user about to over-build infrastructure they do not yet need?
  4. Alternatives / Simplifications — is there a 5th option Claude did not surface?
  5. Test gaps — what would empirically validate the chosen path is right BEFORE big commitments?
- Apply generative-ideation pattern (v2.1):
  - Missing approaches: what fifth/sixth option for "moving forward" did Claude not consider?
  - Cross-domain analogs: what would a startup founder / academic researcher / biotech PM do differently here?
  - Sub-problem decomposition: does the answer change depending on whether the user values product-velocity vs infrastructure-rigor more right now?
  - Ranking reassessment: if forced to pick ONE recommendation, which survives adversarial review best?
- Label each issue:
  - [grounded] = directly observed in code or docs
  - [inferred] = strongly implied by patterns
  - [speculative] = possible but unverified
- Provide 1-3 substantive critiques. If none found, say "no issues found" and state residual risks.
- Always include Open Questions — things neither side may have considered.
- Do NOT execute any changes or edit any files. Text-only critique.

## Output Format

- Issues (ranked by severity, with evidence labels)
- Missing approaches (per generative-ideation pattern)
- Cross-domain analogs
- Sub-problem decomposition
- Ranking reassessment (which single recommendation survives best?)
- Assumptions (only those that materially affect the critique)
- Open Questions
